

Attorney Docket No.: **PM (DC-0251)**
Inventor: **Wade and Demian**
Serial No.: **09/720,078**
Filing Date: **25 July 2001**
Page 3

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-31 (canceled).

Claim 32 (new): A method for enhancing at least the humoral immune response or CD4 Th1 immune response to a target antigen comprising administering the following:

(i) a conjugate comprising a selected antigen, which is directly or indirectly attached to an antibody that specifically binds to a molecule which is expressed by an antigen-presenting cell (APC);

(ii) an anti-CD40 antibody; and

(iii) an adjuvant, wherein the antigen-antibody conjugate of (i), the anti-CD40 antibody of (ii), and the adjuvant of (iii) are administered simultaneously or substantially contemporaneously thereby enhancing at least the humoral immune response or CD4 Th1 immune response to the target antigen when compared to the humoral immune response or CD4 Th1 immune response provided upon administration of the antigen-antibody conjugate in the absence of the anti-CD40 antibody.

Claim 33 (new): The method of claim 32, which is effected *in vivo*.

Claim 34 (new): The method of claim 32, wherein the antigen-antibody conjugate of (i) and the anti-CD40 antibody are administered together.

Attorney Docket No.: **PM (DC-0251)**
Inventor: **Wade and Demian**
Serial No.: **09/720,078**
Filing Date: **25 July 2001**
Page 4

Claim 35 (new): The method of claim 32, wherein the antigen is directly attached to said antibody.

Claim 36 (new): The method of claim 35, wherein said direct attachment comprises covalent attachment of the antigen and the antibody.

Claim 37 (new): The method of claim 32, wherein the administered antigen-antibody conjugate of (i) and the anti-CD40 antibody are contained in the same composition.